🇺🇸 FDA
Patent

US 8168588

Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions

granted A61KA61K38/1808A61K38/1825

Quick answer

US patent 8168588 (Compositions comprising FGF-9 and betacellulin and methods for treating cardiac conditions) held by Five Prime Therapeutics, Inc. expires Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Five Prime Therapeutics, Inc.
Grant date
Tue May 01 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 26 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/1808, A61K38/1825, A61K38/1858, A61K38/1866